clinical trial · NCT03905694
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
Primary HyperoxaluriaPrimary Hyperoxaluria Type 1 (PH1)Lumasiran
brief summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).
started
Apr 22, 2019
primary completion
Jun 29, 2020
completion
Jul 26, 2024
last updated
Feb 14, 2025
official title
ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol